TY - JOUR
T1 - Presentation and management of a patient with subcutaneous metastatic transitional cell carcinoma of the bladder
AU - Alphs, Hannah H.
AU - Miles-Thomas, Jennifer
AU - Attenello, Frank
AU - Taube, Janis M.
AU - Fonseca, Gustavo
AU - Guzzo, Thomas J.
AU - Schoenberg, Mark P.
AU - Bivalacqua, Trinity J.
PY - 2008
Y1 - 2008
N2 - Background: A 60-year-old female with a 6-month history of muscle-invasive transitional cell carcinoma of the bladder presented with an enlarging subcutaneous lesion involving her right flank. She had previously undergone radical cystectomy, bilateral pelvic lymphadenectomy and ileal orthotopic neobladder reconstruction. Investigations: Axial fused fluorodeoxyglucose PET-CT of the chest, abdomen and pelvis, fine needle aspiration with direct ultrasound guidance, excisional biopsy and immunohistochemistry. Diagnosis: Subcutaneous and liver metastases of transitional cell carcinoma. Management: Wide local excision of the subcutaneous lesion followed by combination gemcitabine-cisplatin chemotherapy. Gemcitabine was administered at a dose of 1,000 mg/m2 on days 1, 8, and 15, and cisplatin was administered at a dose of 75 mg/m2 on day 1; the schedule was repeated every 28 days for three cycles.
AB - Background: A 60-year-old female with a 6-month history of muscle-invasive transitional cell carcinoma of the bladder presented with an enlarging subcutaneous lesion involving her right flank. She had previously undergone radical cystectomy, bilateral pelvic lymphadenectomy and ileal orthotopic neobladder reconstruction. Investigations: Axial fused fluorodeoxyglucose PET-CT of the chest, abdomen and pelvis, fine needle aspiration with direct ultrasound guidance, excisional biopsy and immunohistochemistry. Diagnosis: Subcutaneous and liver metastases of transitional cell carcinoma. Management: Wide local excision of the subcutaneous lesion followed by combination gemcitabine-cisplatin chemotherapy. Gemcitabine was administered at a dose of 1,000 mg/m2 on days 1, 8, and 15, and cisplatin was administered at a dose of 75 mg/m2 on day 1; the schedule was repeated every 28 days for three cycles.
UR - http://www.scopus.com/inward/record.url?scp=57449093105&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=57449093105&partnerID=8YFLogxK
U2 - 10.1038/ncpuro1253
DO - 10.1038/ncpuro1253
M3 - Article
C2 - 19002126
AN - SCOPUS:57449093105
SN - 1743-4270
VL - 5
SP - 691
EP - 694
JO - Nature Clinical Practice Urology
JF - Nature Clinical Practice Urology
IS - 12
ER -